文献速递其他结缔组织病

系统性硬化症自体造血干细胞移植后疾病进展的管理:一项国际问卷调查研究结果

Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study.
PubMed 文献 · Semin Arthritis Rheum · 2025-01-31

该国际问卷调查研究纳入来自21个国家的69名系统性硬化症专家,探讨自体造血干细胞移植(AHSCT)后疾病进展的定义、诊断检查及治疗偏好。专家将移植后未改善定义为mRSS增加、新发或加重间质性肺病(ILD)、新发硬皮病肾危象(SRC)或炎性关节炎;初始缓解后进展还包括新发肺动脉高压、指端血管病变或躯体功能受损。移植失败后最常用霉酚酸酯(88.7%)、利妥昔单抗(87.1%)、尼达尼布(62.9%)和/或托珠单抗(58.1%),多数受访者考虑联合治疗(88.4%)。

要点

  • 专家将AHSCT失败定义为mRSS增加、新发或加重ILD、新发SRC或炎性关节炎。
  • 初始缓解后进展还包括新发肺动脉高压、指端血管病变或躯体功能受损。
  • 移植失败后常用霉酚酸酯、利妥昔单抗、尼达尼布和/或托珠单抗,多数考虑联合治疗。

核心结论

  • 本研究总结了系统性硬化症专家在AHSCT后管理方面的独特综合经验,归纳了AHSCT失败和缓解后进展的定义偏好以及诊断检查和治疗方法。

研究设计与样本

  • 一项在线问卷研究,包含17个问题,涉及受访者人口学特征、AHSCT后系统性硬化症进展的定义、诊断检查和治療偏好。
  • 共69名来自21个国家的受访者完成问卷;大多数(89.7%)在大学医院工作,71%参与系统性硬化症患者AHSCT相关决策。
  • 大多数受访者照护过1至5名接受AHSCT的患者。

主要发现

  • 专家将AHSCT后未改善定义为:mRSS增加、新发或加重间质性肺病(ILD)、新发硬皮病肾危象(SRC)或炎性关节炎。
  • 初始缓解后进展定义为:mRSS增加、新发或加重ILD、新发SRC、炎性关节炎、新发肺动脉高压、指端血管病变或躯体功能受损。
  • AHSCT失败时最常用的治疗为霉酚酸酯(N=55,88.7%)、利妥昔单抗(N=54,87.1%)、尼达尼布(N=39,62.9%)和/或托珠单抗(N=36,58.1%)。
  • 大多数受访者(N=61,88.4%)考虑联合使用上述一种以上药物。

关键数值与推荐

  • AHSCT失败(未改善)的定义包括mRSS增加、新发或加重ILD、新发SRC或炎性关节炎。
  • 初始缓解后进展的定义包括mRSS增加、新发或加重ILD、新发SRC、炎性关节炎、新发肺动脉高压、指端血管病变或躯体功能受损。
  • AHSCT失败后最常用霉酚酸酯(N=55,88.7%)、利妥昔单抗(N=54,87.1%)、尼达尼布(N=39,62.9%)和/或托珠单抗(N=36,58.1%)。
  • 多数受访者(N=61,88.4%)考虑联合使用一种以上上述药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autologous stem cell transplantation (AHSCT) is an established treatment in diffuse cutaneous systemic sclerosis (dcSSc). Optimal management of disease progression after AHSCT in dcSSc has not been defined. The aim of this study was to explore the experience and preferences of SSc experts on post-AHSCT management. METHODS: An online questionnaire study was conducted containing 17 questions concerning respondent demographics, definition of SSc progression after AHSCT, diagnostic work-up and treatment preferences. RESULTS: In total, 69 respondents from 21 countries completed the questionnaire. The majority (89.7 %) works at a university hospital, and were involved in decisions regarding AHSCT in patients with SSc (71 %). Most have 1 to 5 patients who underwent AHSCT under their care. They defined failure to improve after AHSCT as: an increase in mRSS, new onset or worsening of interstitial lung disease (ILD), new onset scleroderma renal crisis (SRC) or inflammatory arthritis. Progression after initial response was defined as: increase in mRSS, new or worsening of ILD, new SRC, inflammatory arthritis, new pulmonary arterial hypertension, digital vasculopathy or impaired physical functioning. The most frequent therapy in case of AHSCT failure was mycophenolate mofetil (N = 55, 88.7 %), rituximab (N = 54, 87.1 %), nintedanib (N = 39, 62.9 %) or/and tocilizumab (N = 36, 58.1 %). Combination therapy with more than one of these agents was considered by most respondents (N = 61, 88.4 %). CONCLUSION: Our study benchmarks the unique combined experiences of post-AHSCT management among SSc experts. We summarize preferences regarding definition of AHSCT failure and progression after response, as well as approach to diagnostic work-up and treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Spierings J, Bandini G, Allanore Y, et al. Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study. Semin Arthritis Rheum. 2025. PMID: 39914262. doi:10.1016/j.semarthrit.2025.152638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。